仟源醫藥(300254.SZ):子公司依巴斯汀片通過一致性評價
格隆匯5月27日丨仟源醫藥(300254.SZ)公佈,公司之子公司杭州澳醫保靈藥業有限公司(“澳醫保靈”)近日收到了國家藥品監督管理局核准簽發的“依巴斯汀片”的《藥品補充申請批件》,該藥品通過仿製藥質量與療效一致性評價。
依巴斯汀片適用於伴有或不伴有過敏性結膜炎的過敏性鼻炎(季節性和常年性),以及慢性特發性蕁麻疹的對症治療。該藥品已列入《國家醫保目錄》和《國家基本藥物目錄》。截至本公告披露日,澳醫保靈是依巴斯汀片全國第一家通過一致性評價的企業。
據國家相關政策,通過一致性評價的藥品品種,在藥品招標、醫保支付層面等方面獲得一定支持。因此,澳醫保靈依巴斯汀片通過一致性評價,有利於提高產品市場競爭力,並對公司的經營產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.